cancer-immunotherapy

Documents about cancer-immunotherapy

• ePRO for the Timely Detection of Side Effects in Cancer Patients Undergoing CAR T Immunotherapy#162481ClinicalTrials.gov
• A Clinical and Biological Prospective Database of Patients Treated With Anticancer Immunotherapy and Follow up of Their Immune-related Adverse Events irAE#208455ClinicalTrials.gov
• Circular RNAs in tumorigenesis: an insight into recent research in biogenesis and targeted tumor therapy#215385Europe PMC
• Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer#230413ClinicalTrials.gov
• Pathological response and tumor regression grading following neoadjuvant chemo-immunotherapy and chemotherapy in resectable non-small cell lung cancer.#269552NCBI PubMed Central
• Omitting Clinical Target Volume in Radical Treatment of Unresectable Stage III Non-small Cell Lung Cancer#311126ClinicalTrials.gov
• Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma#311142ClinicalTrials.gov
• Engineered Lipid Nanoparticles with Promoted Endosomal Escape and R283S-Mediated Stimulator of Interferon Genes (STING) Activation for Pancreatic Cancer Immunotherapy.#317875NCBI PubMed Central
• A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma#325311ClinicalTrials.gov
• Essential Updates 2024-2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization.#399640NCBI PubMed Central
• A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC#435737ClinicalTrials.gov
• Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC#444878ClinicalTrials.gov
• Generative AI-driven de novo design of high-affinity, epitope-specific antibodies targeting the CD93-IGFBP7 axis for cancer immunotherapy.#452871NCBI PubMed Central
• Hepatocellular Carcinoma#486867Directory of Open Access Books
• Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)#850320ClinicalTrials.gov
• Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations#387171ClinicalTrials.gov
• Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial#160371ClinicalTrials.gov
• Immunotherapy With Durva and Treme With or Without Capecitabine in Adjuvant Treatment for Biliary Tract Cancer#343816ClinicalTrials.gov
• Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer#826962ClinicalTrials.gov
• Testing the Safety and Feasibility of Immunotherapy Drugs, Botensilimab and Balstilimab, Before Surgery for Clear Cell Renal Cell Carcinoma, NEO RoBOT Trial#180375ClinicalTrials.gov
• Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer#812472ClinicalTrials.gov
• IRIS: Discovery of cancer immunotherapy targets arising from pre-mRNA alternative splicing#492041eScholarship
• A Study of Metronomic CP and JX-594 in Patients With Advanced Breast Cancer and Advanced Soft-tissue Sarcoma (METROmaJX)#850135ClinicalTrials.gov
• Neoadjuvant Chemotherapy in Combination With Toripalimab for HR+/HER2- Breast Cancer : a Randomized, Open-label, Parallel-controlled, Multi-center Phase III Study (NEOTORCH-BREAST04)#864759ClinicalTrials.gov
• Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)#123472ClinicalTrials.gov
• A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer#127592ClinicalTrials.gov
• Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimen#160373ClinicalTrials.gov
• Ingénierie cellulaire de CAR-Macrophages (CAR-M) pour le traitement des tumeurs ET1R positives : application au mélanome#178037HAL (France)
• Knowledge mapping and research trends of chimeric antigen receptor T-cell immunotherapy in breast cancer: A bibliometric and visual analytics study.#305118NCBI PubMed Central
• Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer#311140ClinicalTrials.gov
• Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy#628538ClinicalTrials.gov
• Efficacy hierarchy and absolute survival benefit of first-line immunotherapy in advanced gastric cancer: a meta-analysis and pooled survival analysis.#630984NCBI PubMed Central
• AG Combined With Immunotherapy and SBRT in Patients With Potentially Resectable Pancreatic Cancer#834587ClinicalTrials.gov
• Molecular Analysis and Treatment Options of Thymic Malignancies#849753ClinicalTrials.gov
• Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer#481757ClinicalTrials.gov
• OveRcoming immunosupprEssion aNd rebAlancing the Immune reSponSe in ovAriaN CancEr Study#834911ClinicalTrials.gov
• Study of Anti-PD-L1 in Combination With Chemo(Radio)Therapy for Oesophageal Cancer#825854ClinicalTrials.gov
• Construction of CT Radiomics Model for Predicting the Efficacy of Immunotherapy in Patients With Stage III NSCLC#141001ClinicalTrials.gov
• Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy#174869ClinicalTrials.gov
• Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)#201620ClinicalTrials.gov
• Liver Cancer and Immunotherapy in the Liquid Biopsy Era#208450ClinicalTrials.gov
• Predicting response to neoadjuvant chemotherapy combined with immunotherapy in gastric cancer based on habitat imaging and peritumoral radiomics: a two-center study.#236081NCBI PubMed Central
• Oncofertility in the Age of HER2 Blockade, Immunotherapy, PARP inhibitors, CDK4/6 inhibitors and Endocrine Treatment: Unanswered Questions in Breast Cancer.#244232NCBI PubMed Central
• Th17-mediated antitumor immunity in patient-derived organoid and autologous immune cell cocultures predicts response to immunotherapy in head and neck cancer.#281003NCBI PubMed Central
• The cell cloud: Adopting systems biology concepts in the era of single-cell immunology#335923PLOS
• Research on Predicting the Efficacy of Immunotherapy for Non-small Cell Lung Cancer Based on CT Radiomics and Peripheral Blood Inflammatory Markers.#342464NCBI PubMed Central
• An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread#414475ClinicalTrials.gov
• The clinical value of adding immune checkpoint inhibitors to radiotherapy for cancer: a systematic review and meta-analysis#676304Europe PMC
• Differential effects of BCG-Russia and BCG-TICE on trained immunity: Potential implications for bladder cancer immunotherapy#686603PLOS
• In vivo immune cell engineering from bench to clinical reality#784656Europe PMC